ProfileGDS5678 / 1460448_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 63% 66% 63% 67% 67% 70% 69% 66% 64% 68% 66% 71% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8985665
GSM967853U87-EV human glioblastoma xenograft - Control 23.766563
GSM967854U87-EV human glioblastoma xenograft - Control 33.9539466
GSM967855U87-EV human glioblastoma xenograft - Control 43.7470963
GSM967856U87-EV human glioblastoma xenograft - Control 54.0500867
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0918367
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3710170
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2432469
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9802966
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8074864
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1098368
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9784166
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5086771
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8858765